4:04 PM
 | 
Jan 30, 2019
 |  BC Extra  |  Preclinical News

Moderna's triplet mRNA therapy treats checkpoint inhibitor-resistant tumors in mice

Moderna Inc. (NASDAQ:MRNA) published preclinical data Wednesday showing a triple mRNA combination product has efficacy against solid tumors, including those resistant to checkpoint inhibitors.

The company's mRNA-2752 contains mRNAs encoding IL-23, IL-36γ and OX40L encapsulated in a lipid nanoparticle. Moderna is testing mRNA-2752 as monotherapy or in combination with Imfinzi durvalumab or tremelimumab from AstraZeneca...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >